| Autor: |
Le Garff-Tavernier, M, Herbi, L, de Romeuf, C, Nguyen-Khac, F, Davi, F, Grelier, A, Boudjoghra, M, Maloum, K, Choquet, S, Urbain, R, Vieillard, V, Merle-Béral, H |
| Předmět: |
|
| Zdroj: |
Leukemia (08876924); Jan2014, Vol. 28 Issue 1, p230-233, 4p, 1 Chart, 1 Graph |
| Abstrakt: |
The article presents a study which aims to determine whether ublituximab could be considered an adapted treatment for the group of high-risk chronic lymphocytic leukemia (CLL) patients. It notes that antibody-dependent cellular cytotoxicity (ADCC) efficacy is more dependent on the intrinsic resistance of the CLL target cells than on the natural killer (NK) cell functionality. It concludes that ublituximab showed a promising overall response rate in CLL patients at a relatively low-dose regimen. |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
